These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 36156528)

  • 1. Risk of Gastrointestinal Infections After Initiating Vedolizumab and Anti-TNFα Agents for Ulcerative Colitis.
    Dalal RS; Mitri J; Goodrick H; Allegretti JR
    J Clin Gastroenterol; 2023 Aug; 57(7):714-720. PubMed ID: 36156528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. P074 Comparative Risk of Clostridioides Difficile Infection in Vedolizumab vs anti-TNFa Agents in Biologic-Naïve Patients With Ulcerative Colitis.
    Dalal R; Mitri J; Goodrick H; Allegretti J
    Am J Gastroenterol; 2021 Dec; 116(Suppl 1):S19. PubMed ID: 37461990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does Obesity Influence the Risk of Clostridium difficile Infection Among Patients with Ulcerative Colitis?
    Chandradas S; Khalili H; Ananthakrishnan A; Wayman C; Reidel W; Waalen J; Konijeti GG
    Dig Dis Sci; 2018 Sep; 63(9):2445-2450. PubMed ID: 29779082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective analysis of Clostridium difficile infection in patients with ulcerative colitis in a tertiary hospital in China.
    Xu H; Tang H; Xu T; Xiao M; Li J; Tan B; Yang H; Lv H; Li Y; Qian J
    BMC Gastroenterol; 2019 Jan; 19(1):3. PubMed ID: 30616563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Superior Effectiveness of Tofacitinib Compared to Vedolizumab in Anti-TNF-experienced Ulcerative Colitis Patients: A Nationwide Dutch Registry Study.
    Straatmijer T; Biemans VBC; Visschedijk M; Hoentjen F; de Vries A; van Bodegraven AA; Bodelier A; de Boer NKH; Dijkstra G; Festen N; Horjus C; Jansen JM; Jharap B; Mares W; van Schaik FDM; Ponsioen C; Romkens T; Srivastava N; van der Voorn MMPJA; West R; van der Woude J; Wolvers MDJ; Pierik M; van der Meulen-de Jong AE; Duijvestein M;
    Clin Gastroenterol Hepatol; 2023 Jan; 21(1):182-191.e2. PubMed ID: 35644343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn's disease patients: a German retrospective chart review.
    Helwig U; Mross M; Schubert S; Hartmann H; Brandes A; Stein D; Kempf C; Knop J; Campbell-Hill S; Ehehalt R
    BMC Gastroenterol; 2020 Jul; 20(1):211. PubMed ID: 32640990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vedolizumab and Anti-Tumour Necrosis Factor α Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study.
    Bressler B; Yarur A; Silverberg MS; Bassel M; Bellaguarda E; Fourment C; Gatopoulou A; Karatzas P; Kopylov U; Michalopoulos G; Michopoulos S; Navaneethan U; Rubin DT; Siffledeen J; Singh A; Soufleris K; Stein D; Demuth D; Mantzaris GJ
    J Crohns Colitis; 2021 Oct; 15(10):1694-1706. PubMed ID: 33786600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world Evidence Comparing Tofacitinib and Vedolizumab in Anti-TNF-experienced Patients With Ulcerative Colitis.
    Adimadhyam S; Lewis JD; Simon AL; Wolfe AE; Smith S; Hou L; Moyneur É; Reynolds JS; Toh S; Dobes A; Parlett L; Haynes K; Burris J; Dorand JE; Long MD; Kappelman MD
    Inflamm Bowel Dis; 2024 Apr; 30(4):554-562. PubMed ID: 37358904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of Serious Infections With Vedolizumab Versus Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease.
    Kirchgesner J; Desai RJ; Beaugerie L; Schneeweiss S; Kim SC
    Clin Gastroenterol Hepatol; 2022 Feb; 20(2):314-324.e16. PubMed ID: 33387667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis.
    Lukin D; Faleck D; Xu R; Zhang Y; Weiss A; Aniwan S; Kadire S; Tran G; Rahal M; Winters A; Chablaney S; Koliani-Pace JL; Meserve J; Campbell JP; Kochhar G; Bohm M; Varma S; Fischer M; Boland B; Singh S; Hirten R; Ungaro R; Lasch K; Shmidt E; Jairath V; Hudesman D; Chang S; Swaminath A; Shen B; Kane S; Loftus EV; Sands BE; Colombel JF; Siegel CA; Sandborn WJ; Dulai PS
    Clin Gastroenterol Hepatol; 2022 Jan; 20(1):126-135. PubMed ID: 33039584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of vedolizumab during intravenous induction therapy in ulcerative colitis and Crohn's disease: post hoc analysis of patient-reported outcomes from the VISIBLE 1 and 2 studies.
    D'Haens G; Baert F; Danese S; Kobayashi T; Loftus EV; Sandborn WJ; Dornic Q; Lindner D; Kisfalvi K; Marins EG; Vermeire S
    Eur J Gastroenterol Hepatol; 2024 Apr; 36(4):404-415. PubMed ID: 38417060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Risk of Serious Infections With Tumor Necrosis Factor α Antagonists vs Vedolizumab in Patients With Inflammatory Bowel Diseases.
    Singh S; Heien HC; Herrin J; Dulai PS; Sangaralingham L; Shah ND; Sandborn WJ
    Clin Gastroenterol Hepatol; 2022 Feb; 20(2):e74-e88. PubMed ID: 33640480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease.
    Rosario M; French JL; Dirks NL; Sankoh S; Parikh A; Yang H; Danese S; Colombel JF; Smyth M; Sandborn WJ; Feagan BG; Reinisch W; Sands BE; Sans M; Fox I
    J Crohns Colitis; 2017 Aug; 11(8):921-929. PubMed ID: 28333288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic risk factors for Clostridium difficile infection in ulcerative colitis.
    Ananthakrishnan AN; Oxford EC; Nguyen DD; Sauk J; Yajnik V; Xavier RJ
    Aliment Pharmacol Ther; 2013 Sep; 38(5):522-30. PubMed ID: 23848254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of the Most Cost-effective Position of Vedolizumab Among the Available Biologic Drugs for the Treatment of Ulcerative Colitis.
    Scott FI; Luo M; Shah Y; Lasch K; Vajravelu RK; Mamtani R; Fennimore B; Gerich ME; Lewis JD
    J Crohns Colitis; 2020 Jun; 14(5):575-587. PubMed ID: 31901085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multi-Center Experience of Vedolizumab Effectiveness in Pediatric Inflammatory Bowel Disease.
    Singh N; Rabizadeh S; Jossen J; Pittman N; Check M; Hashemi G; Phan BL; Hyams JS; Dubinsky MC
    Inflamm Bowel Dis; 2016 Sep; 22(9):2121-6. PubMed ID: 27542130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surgical Outcomes in Vedolizumab-Treated Patients with Ulcerative Colitis.
    Lightner AL; McKenna NP; Moncrief S; Pemberton JH; Raffals LE; Mathis KL
    Inflamm Bowel Dis; 2017 Dec; 23(12):2197-2201. PubMed ID: 28858072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Week 2 Symptomatic Response with Vedolizumab as a Predictive Factor in Japanese Anti-TNFα-Naive Patients with Ulcerative Colitis: A post hoc Analysis of a Randomized, Placebo-Controlled Phase 3 Trial.
    Nagahori M; Watanabe K; Motoya S; Ogata H; Kanai T; Matsui T; Suzuki Y; Pinton P; Ursos L; Sakamoto S; Shikamura M; Hori T; Fernandez J; Hibi T; Watanabe M
    Digestion; 2021; 102(5):742-752. PubMed ID: 33454706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium.
    Narula N; Peerani F; Meserve J; Kochhar G; Chaudrey K; Hartke J; Chilukuri P; Koliani-Pace J; Winters A; Katta L; Shmidt E; Hirten R; Faleck D; Parikh MP; Whitehead D; Boland BS; Singh S; Sagi SV; Fischer M; Chang S; Barocas M; Luo M; Lasch K; Bohm M; Lukin D; Sultan K; Swaminath A; Hudesman D; Gupta N; Shen B; Kane S; Loftus EV; Siegel CA; Sands BE; Colombel JF; Sandborn WJ; Dulai PS
    Am J Gastroenterol; 2018 Sep; 113(9):1345. PubMed ID: 29946178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Long-Term Drug Survival of Vedolizumab, Adalimumab, and Infliximab in Biologic-Naïve Patients with Ulcerative Colitis.
    Dalal RS; McClure EL; Marcus J; Allegretti JR
    Dig Dis Sci; 2023 Jan; 68(1):223-232. PubMed ID: 35415826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.